ACXP vs PHAT vs PRAX vs PFE

For growth investors, Phathom Pharmaceuticals, Inc.

(PHAT) is the stronger pick with 216. 9% revenue growth year-over-year, versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). Pfizer Inc. (PFE) offers the better valuation at 19. 5x trailing P/E (8. 9x forward), making it the more compelling value choice. Analysts rate Phathom Pharmaceuticals, Inc. (PHAT) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Pfizer Inc.

(PFE) delivered a total return of -13. 3%, compared to -98. 7% for Acurx Pharmaceuticals, Inc. (ACXP). Over 10 years, the gap is even starker: PFE returned +29. 6% versus ACXP's -98. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Pfizer Inc.

(PFE) is the lower-risk stock at 0. 54β versus Acurx Pharmaceuticals, Inc. 's 2. 42β — meaning ACXP is approximately 345% more volatile than PFE relative to the S&P 500. On balance sheet safety, Praxis Precision Medicines, Inc. (PRAX) carries a lower debt/equity ratio of 0% versus 78% for Pfizer Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Phathom Pharmaceuticals, Inc.

(PHAT) is pulling ahead at 216. 9% versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). On earnings-per-share growth, the picture is similar: Acurx Pharmaceuticals, Inc. grew EPS 69. 8% year-over-year, compared to -32. 0% for Praxis Precision Medicines, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Pfizer Inc.

(PFE) is the more profitable company, earning 12. 4% net margin versus -126. 3% for Phathom Pharmaceuticals, Inc. — meaning it keeps 12. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PFE leads at 24. 7% versus -91. 4% for PHAT. At the gross margin level — before operating expenses — PHAT leads at 87. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for PHAT: 101.

7% to $24. 67.

In this comparison, PFE (6.

5% yield) pays a dividend. ACXP, PHAT, PRAX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Pfizer Inc.

(PFE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 54), 6. 5% yield). Acurx Pharmaceuticals, Inc. (ACXP) carries a higher beta of 2. 42 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PFE: +29. 6%, ACXP: -98. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ACXP is a small-cap quality compounder stock; PHAT is a small-cap high-growth stock; PRAX is a small-cap quality compounder stock; PFE is a mid-cap income-oriented stock. PFE pays a dividend while ACXP, PHAT, PRAX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.